Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Montijo – page 3

673 clinical trials in Montijo, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Montijo at a glance
673
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

673 trials in Montijo

Open in trial search

Study on Spesolimab for Adults with Pyoderma Gangrenosum Requiring Systemic Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Leo Pharma A/S

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Greenwich LifeSciences Inc.

Migraine

Recruiting

Long-term safety study of eptinezumab given by intravenous infusion for children and adolescents aged 6-17 years with chronic or episodic migraine

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Montijo

What the registry says about research in the country

01 Cardiovascular Diseases

Montijo hosts a focused research effort on cardiovascular diseases, with two active recruiting trials at a single site led by a local investigator.

  • Evaluation of zilebesiran in patients with uncontrolled hypertension and established or high‑risk cardiovascular disease
  • Assessment of the antibody combination REGN7508 and REGN9933 for preventing ischemic stroke and systemic embolism in atrial fibrillation patients
  • Investigation of major bleeding risk associated with the REGN antibody therapy
  • Inclusion of participants with atrial fibrillation, established cardiovascular disease, high cardiovascular risk and hypertension

These studies aim to improve outcomes by testing novel therapies and safety profiles, positioning Montijo as a niche hub for cardiovascular innovation in Portugal.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.